Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications
Table 1
Selection of study subjects with newly diagnosed ulcerative proctitis.
Criterion
Total patients
Patients aged ≥18 years who underwent colonoscopy/sigmoidoscopy between January 1, 2005, and December 31, 2007, resulting in a diagnosis of ulcerative proctitis (ICD-9-CM 556.2) or ulcerative proctosigmoiditis (556.3)
11,475
Evidence of receipt of a 5-ASA (oral, enema, or suppository) within 30 days of this procedure (date of first receipt termed “index date”)
2587
≥12 months of complete encounter data before and after index date
1401
No evidence of receipt of a 5-ASA, metronidazole, antimetabolite, glucocorticoid, or TNF inhibitor in the 365 days preceding index date
743
No medical encounters with a primary diagnosis code for ulcerative colitis (ICD-9-CM 556.X, excluding 556.2 and 556.3) and/or Crohn’s disease (ICD-9-CM 555.X or 556.X) 31 to 365 days prior to index date
693
No evidence of receipt of >1 UP-related medication on index date
